BioCentury | Apr 15, 2013
Clinical News

DMUC5754A: Phase I data

...in 44 evaluable patients with advanced recurrent platinum-resistant ovarian cancer showed that 0.3-3.2 mg/kg IV DMUC5754A...
...disease. The complete and partial responses occurred in patients receiving the 2.4 mg/kg dose of DMUC5754A...
...toxicities (DLTs) of grade 4 neutropenia and uric acid increase occurred at the 3.2 mg/kg DMUC5754A...
Items per page:
1 - 1 of 1